MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar TMFMassimo (< 20) Submitted: 7/21/2012 11:18:20 PM : Underperform Start Price: $2.60 MNKD Score: +23.29

I think MannKind is a very risky investment. It's key inhalable insulin product, Afrezza, has been rejected by the FDA twice and won't be approved before 2013. It has been relying on its CEO for cash injections and had major job cuts last year. Its financial status is fragile to say the least. As a scientist, I would love to see Afrezza hit the market and provide diabetics with an additional option. As an investor, this is just too risky for me.

Featured Broker Partners


Advertisement